News & Updates

Liver-directed RT plus atezolizumab-bevacizumab improves response rates in HCC patients

Adding liver-directed radiation therapy (RT) to atezolizumab and bevacizumab (A/B) produces limited additional toxicity with higher response rates among patients with hepatocellular carcinoma (HCC), reports a recent study. However, substantial differences in baseline characteristics hinder a full interpretation of this data.

Childhood ALL burden drops but inequalities persist

The global burden of childhood acute lymphoblastic leukemia (ALL) has gradually decreased, with steady improvements in quality of care, but inequalities remain a significant challenge, according to a study.

Painful, blistering, severe sunburns tied to cutaneous squamous cell carcinoma

Individuals exposed to increased frequencies of painful, blistering, and/or severe sunburns throughout their lifetime have increased odds of cutaneous squamous cell carcinoma (cSCC), according to a systematic review and meta-analysis.

Cancer treatment personalization with biomarkers: What lies ahead?

Metronomic chemo in HR+, HER2- advanced breast cancer after ET

Metronomic chemotherapy (MCT) has gained popularity for maintaining disease control with a more favourable toxicity profile than conventional chemotherapy. In an interview with MIMS Oncology, Dr Michael Cheung, Specialist in Clinical Oncology in private practice in Hong Kong, discussed its benefits for patients with hormone receptor positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) who have failed endocrine therapy (ET).

Pembrolizumab plus chemo efficacious in advanced PSCC

Treatment with the combination of pembrolizumab plus chemotherapy elicits response in patients with advanced penile squamous cell carcinoma (PSCC) while having a manageable safety profile, according to the phase II HERCULES trial.

Multidisciplinary effort facilitates care for ICI-related Sjogren's syndrome

A single-centre study has noted a 1.8-percent incidence of Sjogren's syndrome due to immune checkpoint inhibitors (ICIs). A multidisciplinary team including oncologists, dentists, and rheumatologists, among others, manages care for patients with this condition.